{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-003357","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.242388+00:00","generated_at":"2026-06-06T06:23:29.282363+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Joshua Boger, founder of Vertex, appointed Chair of CervoMed Board; RewinD-LB trial on track","bullets":["Joshua Boger, Ph.D., former CEO and founder of Vertex Pharmaceuticals, appointed as director and Chair of CervoMed Board effective Feb 7, 2024.","CervoMed expects to fully enroll RewinD-LB Phase 2b trial in 1H 2024; topline data for neflamapimod in DLB expected in 2H 2024.","Boger beneficially owns 561,309 shares (~9.90% of CRVO) and pre-funded warrants for 495,995 shares.","Dr. Sylvie Gregoire steps down as Chair but remains on Board.","Boger will receive 10,000 stock option grant and standard non-employee director compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-003357","json":"https://secwatch.observer/filing/0001437749-24-003357.json","markdown":"https://secwatch.observer/filing/0001437749-24-003357.md","text":"https://secwatch.observer/filing/0001437749-24-003357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924003357/0001437749-24-003357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924003357/crvo20240205_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T06:23:29.282363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fddfa75633","claim":"Joshua S. Boger was appointed as Chair of the Board at CervoMed Inc..","evidence_excerpt":"On February 5, 2024, the Board of Directors (the “Board”) of CervoMed Inc. (the “Company”) appointed Joshua S. Boger, Ph.D., as a director of the Company and as Chair of the Board, effective February 7, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924003357/0001437749-24-003357-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chair of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}